

October 29, 2026

Company Name: **Veritas In Silico Inc.**

Representative: **Shingo NAKAMURA,**

Representative Director and CEO

Listed on: TSE Growth

Stock Ticker Code: 130A

Contact : **Tsuneo GODA,**

Executive Officer, General Manager,

Corporate Planning Division

Email: ir@veritasinsilico.com

Notice of Completion of Payment for #5 (with Exercise Price Adjustment Clause) and #6 to #9 Share Acquisition Rights (with Target Issue and Adjustment Options) by Third-Party Allotment

Veritas In Silico Inc. (Headquarters: Shinagawa-ku, Tokyo; Representative Director and CEO: Shingo NAKAMURA, hereinafter referred to as "the Company") hereby announces that it has completed the issuance of #5 through #9 of share acquisition rights (hereinafter referred to as "Share Acquisition Rights") by way of third-party allotment to Long Corridor Alpha Opportunities Master Fund ("LCAO"), an exempted limited liability company established in the Cayman Islands; MAP246 Segregated Portfolio ("MAP246"), a segregated portfolio company established in the Cayman Islands; and BEMAP Master Fund Ltd. ("BEMAP"), an exempted limited liability company established in the Cayman Islands. Each of these investors is managed on a discretionary basis by Long Corridor Asset Management Limited ("LCAM"), an institutional investor based in Hong Kong. LCAO, MAP246 and BEMAP are individually or collectively referred to as the "Allottees."

The issuance and the procedures for entering into the share acquisition rights purchase agreement with the Allottees (the "Purchase Agreement"), subject to the effectiveness of the statutory filing under the Financial Instruments and Exchange Act, were resolved at a meeting of the Company's Board of Directors held on October 13, 2026. The Company has received the payment due upon issuance of the Share Acquisition Rights, totaling 2,801 thousand Yen for the #5 through #9 series.

The Company expects to raise approximately 1,773 million Yen in total through the issuance and exercise of the Share Acquisition Rights. The entire amount is intended to be allocated to development and research expenses from January 2027 through December 2029. These expenses will fund animal studies to evaluate the efficacy and safety of drug candidates, as well as investigator-initiated clinical trials to assess the efficacy and safety of drug candidates and Perfusio[®] when used in humans.

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

These activities form part of the Company's in-house drug discovery research and are intended to support the future out-licensing of the Company's pipeline to pharmaceutical companies in Japan and Overseas.

Over the next approximately three years, the Company aims to obtain trial results demonstrating the efficacy of its drug candidates and treatment approaches utilizing Perfusio[®], and then out-license them to pharmaceutical companies in Japan and Overseas. Through such licensing transactions, the Company seeks to generate licensing income exceeding its development and research investment. Specifically, the Company plans to conduct the above-mentioned animal studies and investigator-initiated clinical trials, including trials that may utilize Perfusio[®], between January 2027 and December 2029 for a total of four programs: three candidates already discovered — (i) a drug targeting the p53 gene for the prevention of acute renal failure following cardiovascular surgery; (ii) a cancer therapeutic targeting the H19 gene; and (iii) an ALS therapeutic targeting the TDP-43 MP13 gene — as well as one additional drug candidate expected to be discovered in 2027. The Company aims to begin out-licensing these programs sequentially from around 2029 and generate revenue.

Please note that, this document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. For further details of the Share Acquisition Rights, please refer to the Company's Japanese-language announcement dated October 13, 2026, entitled "Issuance of #5 (with Exercise Price Adjustment Clause) and #6 to #9 of Share Acquisition Rights (『第三者割当による第5回(行使価額修正条項付)及び第6回から第9回新株予約権(ターゲット・イシュー・修正選択権付)の発行ならびに、新株予約権の買取契約締結のお知らせ』)."

● Summary of the Share Acquisition Rights

<#5 Share Acquisition Rights>

1. Allotment date: October 29, 2026
2. Number of rights to be issued: 30,000 (each right entitles the holder to acquire 100 shares of common stock)
3. Issue price: 2,550,000 Yen in total (85 Yen per right)
4. Potential shares to be issued upon exercise: 3,000,000 shares of common stock (100 shares per right)
5. Estimated proceeds: 1,280,550,000 Yen (Note)

Breakdown: payment upon issuance, 2,550,000 Yen ; proceeds from exercise, 1,278,000,000 Yen.

6. Exercise price and adjustment terms: The initial exercise price is ¥426. From October 30, 2026, if the reference price—being 90% of the closing price of the Company's common stock in regular trading on the Tokyo Stock Exchange on the last trading day of the week preceding the week in which the relevant exercise request is notified (or, if there is no closing price on that day, the immediately preceding closing price), rounded up to the nearest tenth of a yen—is at least ¥0.1 higher or lower than the exercise price then in effect, the exercise price shall be adjusted to such reference price from the relevant adjustment date. If an event requiring adjustment under Item 11 of the terms of issuance occurs between the reference date and the adjustment date, the adjusted exercise price shall reflect such event. Notwithstanding the foregoing, the adjusted exercise price shall not be less than ¥213, subject to adjustment pursuant to Item 11 of the terms of issuance. There is no upper limit on the exercise price.
7. Allotment method and allottees: Third-party allotment as follows: LCAO, 22,200 rights; MAP246, 2,400 rights; BEMAP, 5,400 rights.
8. Exercise period: October 30, 2026 through October 29, 2029. If the final day is not a trading day, the preceding trading day shall be the final day. Exercise requests may not be made during (i) any period in which the book-entry transfer institution deems suspension of exercise necessary, or (ii) any period of up to one month during which exercise is suspended in connection with a corporate reorganization under Item 14 of the terms of issuance, provided that the Company gives the holders at least one month's prior notice of the suspension period and other necessary matters.
9. Other terms: Following the effectiveness of the statutory filing under the Financial Instruments and Exchange Act, the Company entered into an underwriting agreement covering the entire issue with the Allottees. The agreement is expected to provide that any transfer of the Share Acquisition Rights by an Allottee requires the Company's prior written approval.

Note: The estimated proceeds from exercise assume that all rights are exercised at the initial exercise price. If the exercise price is adjusted or otherwise revised, the amount raised may increase or decrease. The amount raised will also vary if the rights are not exercised during the exercise period.

<#6 Share Acquisition Rights>

1. Allotment date: October 29, 2026
2. Number of rights to be issued: 2,000 (each right entitles the holder to acquire 100 shares of common stock)
3. Issue price: 104,000 Yen in total (52 Yen per right)
4. Potential shares to be issued upon exercise: 200,000 shares of common stock (100 shares per right)
5. Estimated proceeds: 120,104,000 Yen (Note 1)
Breakdown: payment upon issuance, 104,000 Yen; proceeds from exercise, 120,000,000 Yen.
6. Exercise price and adjustment terms: Exercise price of 600 Yen (Note 2).
7. Allotment method and allottees: By third-party allotment, following consultation with the Allottees: LCAO, 1,480 rights; MAP246, 160 rights; BEMAP, 360 rights.
8. Exercise period: October 30, 2026 (inclusive) through October 29, 2029 (inclusive). If the final day is not a trading day, the preceding trading day shall be the final day. Exercise requests may not be made during (i) any period in which the book-entry transfer institution deems suspension of exercise necessary, or (ii) any period of up to one month during which exercise is suspended in connection with a corporate reorganization under Item 14 of the terms of issuance, provided that the Company gives the holders at least one month's prior notice of the suspension period and other necessary matters.
9. Other terms: The Company plans to enter into an underwriting agreement covering the entire issue with the Allottees following the effectiveness of the statutory filing under the Financial Instruments and Exchange Act. The agreement will require the Company's prior written approval for any transfer of the rights by an Allottee. No exercise price adjustment mechanism is established at issuance; however, to avoid a material divergence from the market price and to facilitate more practical and effective fundraising, the Company may, if it deems necessary, add an adjustment mechanism by resolution of its Board of Directors. Under such mechanism, the exercise price may be adjusted to 90% of the closing price on the last trading day of the week preceding the week in which the relevant exercise becomes effective, provided that it shall not fall below the applicable floor exercise price.

Note 1: The estimated proceeds assume that all rights are exercised at the stated exercise price. If the exercise price is adjusted or otherwise revised, the amount raised may increase or decrease. The amount raised will also vary if the rights are not exercised during the exercise period.

Note 2: The exercise price of #6 has been set to indicate the share-price level the Company seeks to achieve over the medium to long term as it pursues management with an awareness of its share price.

<#7 Share Acquisition Rights>

1. Allotment date: October 29, 2026
2. Number of rights to be issued: 2,000 (each right entitles the holder to acquire 100 shares of common stock)
3. Issue price: 78,000 Yen in total (39 Yen per right)
4. Potential shares to be issued upon exercise: 200,000 shares of common stock (100 shares per right)
5. Estimated proceeds: 160,078,000 Yen (Note 1)
Breakdown: payment upon issuance, 78,000 Yen; proceeds from exercise, 160,000,000 Yen.
6. Exercise price and adjustment terms: Exercise price of 800 Yen (Note 2).
7. Allotment method and allottees: By third-party allotment, following consultation with the Allottees: LCAO, 1,480 rights; MAP246, 160 rights; BEMAP, 360 rights.
8. Exercise period: October 30, 2026 (inclusive) through October 29, 2029 (inclusive). If the final day is not a trading day, the preceding trading day shall be the final day. Exercise requests may not be made during (i) any period in which the book-entry transfer institution deems suspension of exercise necessary, or (ii) any period of up to one month during which exercise is suspended in connection with a corporate reorganization under Item 14 of the terms of issuance, provided that the Company gives the holders at least one month's prior notice of the suspension period and other necessary matters.
9. Other terms: The Company plans to enter into an underwriting agreement covering the entire issue with the Allottees following the effectiveness of the statutory filing under the Financial Instruments and Exchange Act. The agreement will require the Company's prior written approval for any transfer of the rights by an Allottee. No exercise price adjustment mechanism is established at issuance; however, to avoid a material divergence from the market price and to facilitate more practical and effective fundraising, the Company may, if it deems necessary, add an adjustment mechanism by resolution of its Board of Directors. Under such mechanism, the exercise price may be adjusted to 90% of the closing price on the last trading day of the week preceding the week in which the relevant exercise becomes effective, provided that it shall not fall below the applicable floor exercise price.

Note 1: The estimated proceeds assume that all rights are exercised at the stated exercise price. If the exercise price is adjusted or otherwise revised, the amount raised may increase or decrease. The amount raised will also vary if the rights are not exercised during the exercise period.

Note 2: The exercise price of #7 has been set to indicate the share-price level the Company seeks to achieve over the medium to long term as it pursues management with an awareness of its share price.

<#8 Share Acquisition Rights>

1. Allotment date: October 29, 2026
2. Number of rights to be issued: 1,000 (each right entitles the holder to acquire 100 shares of common stock)
3. Issue price: 35,000 Yen in total (35 Yen per right)
4. Potential shares to be issued upon exercise: 100,000 shares of common stock (100 shares per right)
5. Estimated proceeds: 100,035,000 Yen (Note 1)
Breakdown: payment upon issuance, 35,000 Yen; proceeds from exercise, 100,000,000 Yen.
6. Exercise price and adjustment terms: Exercise price of 1,000 Yen (Note 2).
7. Allotment method and allottees: By third-party allotment, following consultation with the Allottees: LCAO, 740 rights; MAP246, 80 rights; BEMAP, 180 rights.
8. Exercise period: October 30, 2026 (inclusive) through October 29, 2029 (inclusive). If the final day is not a trading day, the preceding trading day shall be the final day. Exercise requests may not be made during (i) any period in which the book-entry transfer institution deems suspension of exercise necessary, or (ii) any period of up to one month during which exercise is suspended in connection with a corporate reorganization under Item 14 of the terms of issuance, provided that the Company gives the holders at least one month's prior notice of the suspension period and other necessary matters.
9. Other terms: The Company plans to enter into an underwriting agreement covering the entire issue with the Allottees following the effectiveness of the statutory filing under the Financial Instruments and Exchange Act. The agreement will require the Company's prior written approval for any transfer of the rights by an Allottee. No exercise price adjustment mechanism is established at issuance; however, to avoid a material divergence from the market price and to facilitate more practical and effective fundraising, the Company may, if it deems necessary, add an adjustment mechanism by resolution of its Board of Directors. Under such mechanism, the exercise price may be adjusted to 90% of the closing price on the last trading day of the week preceding the week in which the relevant exercise becomes effective, provided that it shall not fall below the applicable floor exercise price.

Note 1: The estimated proceeds assume that all rights are exercised at the stated exercise price. If the exercise price is adjusted or otherwise revised, the amount raised may increase or decrease. The amount raised will also vary if the rights are not exercised during the exercise period.

Note 2: The exercise price of #8 has been set as an indication of the share-price level the Company seeks to achieve over the medium to long term, and is based on the public offering price at the Company's listing on the Tokyo Stock Exchange Growth Market in February 2024.

<#9 Share Acquisition Rights>

1. Allotment date: October 29, 2026
2. Number of rights to be issued: 1,000 (each right entitles the holder to acquire 100 shares of common stock)
3. Issue price: 34,000 Yen in total (¥34 per right)
4. Potential shares to be issued upon exercise: 100,000 shares of common stock (100 shares per right)
5. Estimated proceeds: 125,034,000 Yen (Note 1)
Breakdown: payment upon issuance, 34,000 Yen; proceeds from exercise, 125,000,000 Yen.
6. Exercise price and adjustment terms: Exercise price of 1,250 Yen (Note 2).
7. Allotment method and allottees: By third-party allotment, following consultation with the Allottees: LCAO, 740 rights; MAP246, 80 rights; BEMAP, 180 rights.
8. Exercise period: October 30, 2026 (inclusive) through October 29, 2029 (inclusive). If the final day is not a trading day, the preceding trading day shall be the final day. Exercise requests may not be made during (i) any period in which the book-entry transfer institution deems suspension of exercise necessary, or (ii) any period of up to one month during which exercise is suspended in connection with a corporate reorganization under Item 14 of the terms of issuance, provided that the Company gives the holders at least one month's prior notice of the suspension period and other necessary matters.
9. Other terms: The Company plans to enter into an underwriting agreement covering the entire issue with the Allottees following the effectiveness of the statutory filing under the Financial Instruments and Exchange Act. The agreement will require the Company's prior written approval for any transfer of the rights by an Allottee. No exercise price adjustment mechanism is established at issuance; however, to avoid a material divergence from the market price and to facilitate more practical and effective fundraising, the Company may, if it deems necessary, add an adjustment mechanism by resolution of its Board of Directors. Under such mechanism, the exercise price may be adjusted to 90% of the closing price on the last trading day of the week preceding the week in which the relevant exercise becomes effective, provided that it shall not fall below the applicable floor exercise price.

Note 1: The estimated proceeds assume that all rights are exercised at the stated exercise price. If the exercise price is adjusted or otherwise revised, the amount raised may increase or decrease. The amount raised will also vary if the rights are not exercised during the exercise period.

Note 2: The exercise price of the ninth series has been set to indicate the share-price level the Company seeks to achieve over the medium to long term, and is based on the price of the paid third-party allotment conducted on December 24, 2021.

END

For Further Information, Contact:

- Veritas In Silico Website Inquiry Form : <https://www.veritasinsilico.com/en/contact/>